TEL AVIV, July 24 Israel-based Atox Bio, a
developer of therapeutics for severe infections, said on
Thursday it has raised $23 million in an investment round led by
SR One, the healthcare venture capital fund of GlaxoSmithKline
Lundbeck's Lundbeckfond Ventures and OrbiMed Israel
The funds will enable Atox Bio to initiate a late stage
clinical study of AB103, for the treatment of necrotising soft
tissue infections (NSTI), commonly referred to as the "flesh
eating bacteria" and other severe infections. The study is
expected to start in the second half of 2015.
AB103, an immunomodulator licensed from Yissum, the
technology transfer company of the Hebrew University In
Jerusalem, is a peptide that offers a unique approach in the
treatment of infectious diseases by modulating, but not
inhibiting, the host immune system.
This approach precludes the rapid generation of drug
resistance, the company said.
AB103 completed a Phase 2 study in patients with NSTI.
"The results demonstrated that patients treated with AB103
had a meaningful improvement across multiple end points," Atox
AB103 is the first product specifically developed for NSTI
and has received orphan drug status and fast track designation
from the U.S. Food and Drug Administration.
"If approved, this treatment could help thousands of
patients each year who suffer the debilitating consequences of
NSTI," said Matthew Foy, partner at SR One.
(Reporting by Tova Cohen)